Parnell Pharmaceuticals Holdings Ltd. (NASDAQ: PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical … Continue reading →

Histogenics Corp. (NASDAQ: HSGX) is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide … Continue reading →

RespireRx Pharmaceuticals, Inc. (OTC: CORX), formerly Cortex Pharmaceuticals, Inc., has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression – areas where current treatment options are … Continue reading →

Synthetic Biologics, Inc. (NYSE: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. One of the company’s lead candidates in phase 2 development is SYN-004, which is designed to protect the gut … Continue reading →

Israel-based BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company committed to identifying, in-licensing and developing promising therapeutic candidates. The company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical … Continue reading →

Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations, and compounds that provide therapies for chronic inflammatory disease and neurologic disorders. Rock Creek’s lead compound, Anatabine … Continue reading →

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late stage pharmaceutical company focused on developing and selling Locilex (pexiganan cream 0.8%), a potent and broad spectrum topical antibiotic peptide, for the treatment of mild and moderate skin and skin structure infections. … Continue reading →

TapImmune Inc. (OTC: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company’s peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively … Continue reading →

TiGenix NV (NYSE: TIG) is a European cell therapy company with an advanced clinical stage pipeline of adult stem cell programs, and a commercialized product. The stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells … Continue reading →

Mymetics Corp. (OTC: MYMX) is a Switzerland-based biotechnology company focused on the development of next-generation preventative vaccines for infectious diseases. The company’s vaccines are designed to induce protection against early transmission and infection. They focus on the mucosal immune response … Continue reading →